Evidence map›Paper›PMID 40722038›Full record

ArticleJournal of translational medicine2025

T cell receptor-like antibody specifically targets and eliminates cells infected with cytomegalovirus.

Dabing Chen, Caidong Hu, Yunda Hong, Jingjing Xu, Jiaqi Sun, Jinhua Ren, Yangtao Wu, Ningshao Xia, Quan Yuan, Jianda Hu and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Dabing Chen *National Regional Medical Center, The Second Department of Hematology, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, P.R. China.
Caidong Hu *National Regional Medical Center, The Second Department of Hematology, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, P.R. China.
Yunda Hong *Institute of Precision Medicine, Fujian Medical University, Fuzhou, P.R. China.
Jingjing XuDepartment of Hepatic Oncology, Zhongshan Hospital, Fudan University (Xiamen Branch), Xiamen, China.
Jiaqi SunNational Regional Medical Center, The Second Department of Hematology, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, P.R. China.
Jinhua RenNational Regional Medical Center, The Second Department of Hematology, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, P.R. China.
Yangtao WuState Key Laboratory of Vaccines for infectious Diseases, Xiang An Biomedicine Laboratory, Department of Laboratory Medicine, School of Public Health, Xiamen University, Xiamen, China.
Ningshao XiaState Key Laboratory of Vaccines for infectious Diseases, Xiang An Biomedicine Laboratory, Department of Laboratory Medicine, School of Public Health, Xiamen University, Xiamen, China. nsxia@xmu.edu.cn.
Quan YuanState Key Laboratory of Vaccines for infectious Diseases, Xiang An Biomedicine Laboratory, Department of Laboratory Medicine, School of Public Health, Xiamen University, Xiamen, China. yuanquan@xmu.edu.cn.
Jianda HuNational Regional Medical Center, The Second Department of Hematology, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, P.R. China. drjiandahu@163.com.
Ting YangNational Regional Medical Center, The Second Department of Hematology, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, P.R. China. yang.hopeting@gmail.com.ORCID 0009-0002-5428-5622

Funding

Fujian Provincial Department of Science and Technology 2023Y9079National Natural Science Foundation of China U23A20419Startup Fund for Scientific Research Project of Fujian Medical University 2023QH2027The Talent Scientific Research Project of the First Affiliated Hospital of Fujian Medical University YJRC4415
6 · The paper itself

Abstract

backgroundCytomegalovirus (CMV) infection, with limited therapeutic options, represents a significant complication following transplantation. T cell receptor (TCR)-like antibodies that can recognize and bind to viral peptides presented by the human leukocyte antigen (HLA) show promise for specifically targeting and eliminating CMV-infected cells. Here, we show that this humanized TCR-like antibody efficiently targets CMV-infected cells, thereby supporting the development of this novel and effective therapeutic option for patients.

methodsUsing a synthetically produced pCMV-pp65

resultsIn this study, we produced and characterized a TCR-like antibody, 3D7, specific for the pCMV-pp65

conclusionsIn conclusion, the TCR-like antibody targeting pCMV-pp65

Indexed as

CytomegalovirusCytomegalovirus InfectionsReceptors, Antigen, T-CellAnimalsHLA-A2 AntigenHumansMiceHLA-A2 AntigenReceptors, Antigen, T-CellAntibody therapyCytomegalovirusImmunotherapyTCR-like antibody

Identifiers

PMID40722038
PMCPMC12306020

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.